OTC · BMXXY
Healthcare · Medical - Specialties
$8.74
Up+$0.00 (+0.00%)
Updated Sep 18, 2026, 9:14 AM
SID Score
5.2/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BMXXY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BMXXY.
BMXXY research
Company profile and research snapshot.
BIOMERIEUX S A UNSP/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 9, 2026 | ODDO BHF | Buy | — |
| Jul 8, 2026 | ESN/CIC MARKET SOLUTIONS | Buy | — |
| Jun 7, 2026 | BAADER EUROPE / ALPHAVALUE | Buy | — |
| Feb 27, 2026 | ODDO BHF | Buy | — |
| Feb 27, 2026 | MIDCAP PARTNERS | Buy | — |
No generated briefing is available yet.
Yahoo · Jul 28, 2026
BioMerieux SA (BMXMF) reports robust free cash flow growth and strategic product launches, while navigating regional market fluctuations and competitive pressures.
SeekingAlpha · Jul 28, 2026
2026-07-28. The following slide deck was published by bioMérieux S.A.
Yahoo · Jun 18, 2026
bioMérieux, a world leader in the field of in vitro diagnostics, today introduces the launch of GENE-UP® TYPER SLM, a new real-time PCR solution supporting rapid root cause analysis by discriminating Salmonella in the food industry environments.
SeekingAlpha · Mar 2, 2026
2026-03-02. The following slide deck was published by bioMérieux S.A.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BMXXY.
